Bone Biologics Corp. (NASDAQ:BBLG) Short Interest Up 646.3% in August

Posted by Stanley Muller on Aug 27th, 2026

Bone Biologics Corp. (NASDAQ:BBLG – Get Free Report) was the recipient of a large increase in short interest during the month of August. As of August 14th, there was short interest totaling 156,590 shares, an increase of 646.3% from the July 30th total of 20,981 shares. Based on an average daily volume of 1,559,990 shares, the days-to-cover ratio is presently 0.1 days. Approximately 6.0% of the shares of the stock are short sold.

Institutional Investors Weigh In On Bone Biologics

A hedge fund recently raised its stake in Bone Biologics stock. DRW Securities LLC increased its position in shares of Bone Biologics Corp. (NASDAQ:BBLG – Free Report) by 113.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,576 shares of the company’s stock after acquiring an additional 12,549 shares during the quarter. DRW Securities LLC owned about 1.31% of Bone Biologics worth $34,000 at the end of the most recent quarter. Institutional investors own 34.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bone Biologics in a research note on Friday, July 24th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Check Out Our Latest Stock Report on BBLG

Bone Biologics Price Performance

Shares of BBLG stock traded down $0.01 during trading hours on Thursday, reaching $0.60. 34,595 shares of the company were exchanged, compared to its average volume of 139,481. Bone Biologics has a fifty-two week low of $0.58 and a fifty-two week high of $4.13. The stock’s fifty day moving average is $1.07 and its two-hundred day moving average is $1.19. The company has a market cap of $1.66 million, a price-to-earnings ratio of -0.44 and a beta of 0.92.

Bone Biologics (NASDAQ:BBLG – Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.04). On average, research analysts anticipate that Bone Biologics will post -1.23 earnings per share for the current year.

About Bone Biologics

(Get Free Report)

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.